Mori, H.; Tanoue, S.; Takaji, R.; Ueda, S.; Okahara, M.; Ueda, S.S.
Arterial Administration of DNA Crosslinking Agents with Restraint of Homologous Recombination Repair by Intravenous Low-Dose Gemcitabine Is Effective for Locally Advanced Pancreatic Cancer. Cancers 2022, 14, 220.
https://doi.org/10.3390/cancers14010220
AMA Style
Mori H, Tanoue S, Takaji R, Ueda S, Okahara M, Ueda SS.
Arterial Administration of DNA Crosslinking Agents with Restraint of Homologous Recombination Repair by Intravenous Low-Dose Gemcitabine Is Effective for Locally Advanced Pancreatic Cancer. Cancers. 2022; 14(1):220.
https://doi.org/10.3390/cancers14010220
Chicago/Turabian Style
Mori, Hiromu, Shuichi Tanoue, Ryo Takaji, Shinya Ueda, Mika Okahara, and Saori Sugi Ueda.
2022. "Arterial Administration of DNA Crosslinking Agents with Restraint of Homologous Recombination Repair by Intravenous Low-Dose Gemcitabine Is Effective for Locally Advanced Pancreatic Cancer" Cancers 14, no. 1: 220.
https://doi.org/10.3390/cancers14010220
APA Style
Mori, H., Tanoue, S., Takaji, R., Ueda, S., Okahara, M., & Ueda, S. S.
(2022). Arterial Administration of DNA Crosslinking Agents with Restraint of Homologous Recombination Repair by Intravenous Low-Dose Gemcitabine Is Effective for Locally Advanced Pancreatic Cancer. Cancers, 14(1), 220.
https://doi.org/10.3390/cancers14010220